Harvard Bioscience (HBIO) Total Non-Current Liabilities (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Total Non-Current Liabilities data on file, last reported at $66.7 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 5.03% year-over-year to $66.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.7 million (up 5.03% YoY) and the FY2025 annual result came in at $65.0 million, up 4.8% from the prior year.
• Total Non-Current Liabilities grew to $66.7 million in Q1 2026 per HBIO's latest filing, from $65.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $81.1 million in Q1 2022 and bottomed at $60.1 million in Q2 2024.
• The 5-year median for Total Non-Current Liabilities is $64.6 million (2023), against an average of $67.0 million.
• The widest annual swing landed in 2022, when Total Non-Current Liabilities rose 13.73%; it then declined 14.07% in 2023.
• Tracing HBIO's Total Non-Current Liabilities over 5 years: stood at $72.1 million in 2022, then retreated by 12.92% to $62.8 million in 2023, then declined by 1.22% to $62.0 million in 2024, then grew by 4.8% to $65.0 million in 2025, then grew by 2.64% to $66.7 million in 2026.
• Per Business Quant, the three latest HBIO Total Non-Current Liabilities figures stand at $66.7 million (Q1 2026), $65.0 million (Q4 2025), and $62.5 million (Q3 2025).

Peer Comparison